
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Brand and product security technologies offer pharmaceutical manufacturers anticounterfeiting solutions.
over 24 years ago
Excipient GMP Quality Standards: One is Enoughover 24 years ago
The IPEC-Americas Excipient Master File Guideover 24 years ago
Calibration of Lyophilization Pressure Gaugesover 24 years ago
Drug Shortages Reveal GMP Concernsover 24 years ago
Outsourcing Outlookover 24 years ago
Optimizing Cross-Organizational Team Performance and Managementover 24 years ago
Screening for Counterfeit Drugs Using Near-Infrared Spectroscopyover 24 years ago
Building on Tradition: Integrating the Links of Expertise




